News

Sanofi-GSK report positive interim results for their COVID-19 shot
May 17, 2021 — An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday... MORE

A servicemember sits in a yellow shirt in front of a table of red and blue testing vials. Covi

JPM CBRN Medical’s RAIDR RF Innovates DOD Medical Acquisition, Wins BRONZE at 2021 Edison Awards
May 14, 2021 — The annual Edison Awards competition is dedicated to honoring excellence and showcasing game-changing innovations that are rapidly reshaping the evolving world around us. An Edison Award recognition is one of the highest accolades an organization can receive, and the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical... MORE

Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
May 12, 2021 — Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays... MORE

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
May 10, 2021 — INO-4800 was shown to be safe, well-tolerated and immunogenic in all age groups. Phase 2 results informed INOVIO's selection of 2.0 mg dose for the Phase 3 segment of the trial... MORE

In the foreground a hand holding an orange sticker that says "I got my vaccine". In the background there are three medical personnel wearing personal protective equipment.

JPEO-CBRND, JPM CBRN Medical Leads DOD Ebola Outbreak Response Efforts
April 28, 2021 — DISCLAIMER: Included references to commercial products does not constitute endorsement by the U.S. Department of Defense or the JPEO-CBRND. The year 2020 will undoubtedly be remembered as the year of the pandemic; the year the world was turned upside down by COVID-19. However, lurking in the shadows and out of the limelight, another viral outbreak... MORE

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 26, 2021 — In July 2020, Immunome was awarded a $13.3 million agreement from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program. The research discussed in this press release is part of that program... MORE

JPM CBRN MEDICAL WINS BRONZE AT 2021 EDISON AWARDS
April 22, 2021 — RAIDR RF innovates and streamlines DOD medical acquisition... MORE

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
April 21, 2021 — https://finance.yahoo.com/news/sab-biotherapeutics-doses-first-patient-200200245.html MORE

Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics.

SecondWave Systems secures over $7 Million from Department of Defense to Accelerate Development and Clinical Study of Novel Anti-Inflammatory Therapy based on Low-Intensity Focused Ultrasound Technology
April 20, 2021 — https://www.businesswire.com/news/home/20210420005207/en/SecondWave-Systems-secures-over-7-Million-from-Department-of-Defense-to-Accelerate-Development-and-Clinical-Study-of-Novel-Anti-Inflammatory-Therapy-based-on-Low-Intensity-Focused-Ultrasound-Technology MORE

Microbiologics Expands Virology Services to Support Drug and Vaccine Researchers and Developers
April 14, 2021 — Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens... MORE

News Search

News Archive - Search by Year and Month

April 2024 (1)
March 2024 (3)
February 2024 (3)
January 2024 (2)
December 2023 (2)
November 2023 (2)
October 2023 (5)
September 2023 (6)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.